SignalXSignalX

GERN GERON CORP

FY2025 10-K
Filed: Mar 2, 2026
Health Care
Pharmaceutical PreparationsSEC EDGAR
GERON CORP Overview

GERON CORP (GERN) filed its fiscal year 2025 10-K annual report with the SEC on Mar 2, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model: Biopharmaceutical company focused on cancer therapeutics development
  • • No new products, services, or segments introduced or emphasized in this filing year
+3 more insights

Management Discussion & Analysis

  • • No revenue or profitability figures disclosed in MD&A section
  • • No segment performance or dollar amounts provided
+3 more insights

Risk Factors

  • • Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation
  • • Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations
+3 more insights

Get deeper insights on GERON CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available